<DOC>
	<DOC>NCT02000947</DOC>
	<brief_summary>The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This is a multicenter, open-label, dose-escalation, and dose expansion study of MEDI4736 in combination with tremelimumab to evaluate the safety, tolerability, pharmacokinetic (PK), immunogenicity, and antitumor activity of MEDI4736 in combination with tremelimumab in adult subjects with advanced NSCLC.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1. Age â‰¥ 18 years 2. Advanced nonsmall cell lung cancer 3. Eastern Cooperative Oncology Group (ECOG) performance status of 01 4. Adequate organ and marrow function 1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment 2. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs 3. Active or prior documented autoimmune disease within the last 2 years.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>anti-CTLA-4</keyword>
	<keyword>anti-PD-L1</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>IMTC</keyword>
</DOC>